Stock Comparison

EXEL vs JNJ

Exelixis Inc vs Johnson & Johnson

The Verdict

JNJ takes this one.

EXEL

Exelixis Inc

0.9

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$12.6B

Market Cap

$557.1B

15.1

P/E Ratio

26.5

35.1%

Profit Margin

21.8%

40.2%

Return on Equity

26.3%

N/A

Debt-to-Equity

0.6

Moderate-High

Overall Risk

Conservative

0.9

DVR Score

1.0

The Deep Dive

EXEL0.9/10

Exelixis continues to demonstrate robust financial performance, driven by its flagship oncology drug, Cabometyx, which showed an 8.1% YoY increase in net product revenues. The company's Q1 2026 results exceeded EPS consensus and delivered strong YoY net income growth of 31.9%. A significant catalyst is the FDA's acceptance of the NDA for zanzalintinib (XL092) in metastatic colorectal cancer, with ...

Full EXEL Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.